Time course of depression-symptom improvement during treatment with duloxetine

Robert M A Hirschfeld, Craig Mallinckrodt, Thomas C. Lee, Michael J. Detke

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The aim of this study was to examine the longitudinal response for overall and individual symptoms during the treatment of major depressive disorder. Data were pooled from two 9-week trials, which compared duloxetine 60-mg QD (n = 251) with placebo (n = 261) in the treatment of MDD. Changes from baseline in the 17-item Hamilton Depression Rating Scale (HAMD17) and in the Visual Analog Scales for pain were analyzed. Compared to placebo-treated patients, duloxetine-treated patients experienced greater improvement (P < .05) in the HAMD17 total score at Week 2. The individual symptoms showing the most rapid improvements (Week 1) were depressed mood, guilt, suicidal ideation, work/activities, and psychic anxiety as well as VAS back pain and shoulder pain. At subsequent visits, significant improvements were observed in retardation (Week 2); hypochondriasis (Week 3); general somatic symptoms (Week 5); middle and late insomnia (Week 7); and gastrointestinal (GI) symptoms, genital symptoms (level of sexual interest or ease of sexual arousal), insight, and early insomnia (Week 9). Significant advantages for duloxetine were not achieved at any visit for agitation, somatic anxiety, or weight loss. At Weeks 1 and 2, placebo-treated patients had significantly lower GI symptoms and reported less weight loss compared with duloxetine-treated patients; however, differences were not significant at subsequent visits. Furthermore, duloxetine was superior to placebo on GI symptoms at endpoint compared to placebo-treated patients; duloxetine-treated patients had a significantly higher response rate at Week 2 and a higher remission rate at Week 5. These results may help clinicians establish more accurate expectations regarding treatment with duloxetine.

Original languageEnglish (US)
Pages (from-to)170-177
Number of pages8
JournalDepression and Anxiety
Volume21
Issue number4
DOIs
StatePublished - 2005

Fingerprint

Depression
Placebos
Sleep Initiation and Maintenance Disorders
Therapeutics
Weight Loss
Anxiety
Hypochondriasis
Suicidal Ideation
Shoulder Pain
Guilt
Major Depressive Disorder
Pain Measurement
Back Pain
Duloxetine Hydrochloride
Arousal

Keywords

  • Antidepressant
  • Depression
  • Duloxetine
  • Efficacy
  • Norepinephrine
  • Onset
  • Pain
  • Serotonin

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Psychology(all)
  • Clinical Psychology

Cite this

Hirschfeld, R. M. A., Mallinckrodt, C., Lee, T. C., & Detke, M. J. (2005). Time course of depression-symptom improvement during treatment with duloxetine. Depression and Anxiety, 21(4), 170-177. https://doi.org/10.1002/da.20071

Time course of depression-symptom improvement during treatment with duloxetine. / Hirschfeld, Robert M A; Mallinckrodt, Craig; Lee, Thomas C.; Detke, Michael J.

In: Depression and Anxiety, Vol. 21, No. 4, 2005, p. 170-177.

Research output: Contribution to journalArticle

Hirschfeld, RMA, Mallinckrodt, C, Lee, TC & Detke, MJ 2005, 'Time course of depression-symptom improvement during treatment with duloxetine', Depression and Anxiety, vol. 21, no. 4, pp. 170-177. https://doi.org/10.1002/da.20071
Hirschfeld, Robert M A ; Mallinckrodt, Craig ; Lee, Thomas C. ; Detke, Michael J. / Time course of depression-symptom improvement during treatment with duloxetine. In: Depression and Anxiety. 2005 ; Vol. 21, No. 4. pp. 170-177.
@article{f057ec574e084506a67578abd1d75bad,
title = "Time course of depression-symptom improvement during treatment with duloxetine",
abstract = "The aim of this study was to examine the longitudinal response for overall and individual symptoms during the treatment of major depressive disorder. Data were pooled from two 9-week trials, which compared duloxetine 60-mg QD (n = 251) with placebo (n = 261) in the treatment of MDD. Changes from baseline in the 17-item Hamilton Depression Rating Scale (HAMD17) and in the Visual Analog Scales for pain were analyzed. Compared to placebo-treated patients, duloxetine-treated patients experienced greater improvement (P < .05) in the HAMD17 total score at Week 2. The individual symptoms showing the most rapid improvements (Week 1) were depressed mood, guilt, suicidal ideation, work/activities, and psychic anxiety as well as VAS back pain and shoulder pain. At subsequent visits, significant improvements were observed in retardation (Week 2); hypochondriasis (Week 3); general somatic symptoms (Week 5); middle and late insomnia (Week 7); and gastrointestinal (GI) symptoms, genital symptoms (level of sexual interest or ease of sexual arousal), insight, and early insomnia (Week 9). Significant advantages for duloxetine were not achieved at any visit for agitation, somatic anxiety, or weight loss. At Weeks 1 and 2, placebo-treated patients had significantly lower GI symptoms and reported less weight loss compared with duloxetine-treated patients; however, differences were not significant at subsequent visits. Furthermore, duloxetine was superior to placebo on GI symptoms at endpoint compared to placebo-treated patients; duloxetine-treated patients had a significantly higher response rate at Week 2 and a higher remission rate at Week 5. These results may help clinicians establish more accurate expectations regarding treatment with duloxetine.",
keywords = "Antidepressant, Depression, Duloxetine, Efficacy, Norepinephrine, Onset, Pain, Serotonin",
author = "Hirschfeld, {Robert M A} and Craig Mallinckrodt and Lee, {Thomas C.} and Detke, {Michael J.}",
year = "2005",
doi = "10.1002/da.20071",
language = "English (US)",
volume = "21",
pages = "170--177",
journal = "Depression and Anxiety",
issn = "1091-4269",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Time course of depression-symptom improvement during treatment with duloxetine

AU - Hirschfeld, Robert M A

AU - Mallinckrodt, Craig

AU - Lee, Thomas C.

AU - Detke, Michael J.

PY - 2005

Y1 - 2005

N2 - The aim of this study was to examine the longitudinal response for overall and individual symptoms during the treatment of major depressive disorder. Data were pooled from two 9-week trials, which compared duloxetine 60-mg QD (n = 251) with placebo (n = 261) in the treatment of MDD. Changes from baseline in the 17-item Hamilton Depression Rating Scale (HAMD17) and in the Visual Analog Scales for pain were analyzed. Compared to placebo-treated patients, duloxetine-treated patients experienced greater improvement (P < .05) in the HAMD17 total score at Week 2. The individual symptoms showing the most rapid improvements (Week 1) were depressed mood, guilt, suicidal ideation, work/activities, and psychic anxiety as well as VAS back pain and shoulder pain. At subsequent visits, significant improvements were observed in retardation (Week 2); hypochondriasis (Week 3); general somatic symptoms (Week 5); middle and late insomnia (Week 7); and gastrointestinal (GI) symptoms, genital symptoms (level of sexual interest or ease of sexual arousal), insight, and early insomnia (Week 9). Significant advantages for duloxetine were not achieved at any visit for agitation, somatic anxiety, or weight loss. At Weeks 1 and 2, placebo-treated patients had significantly lower GI symptoms and reported less weight loss compared with duloxetine-treated patients; however, differences were not significant at subsequent visits. Furthermore, duloxetine was superior to placebo on GI symptoms at endpoint compared to placebo-treated patients; duloxetine-treated patients had a significantly higher response rate at Week 2 and a higher remission rate at Week 5. These results may help clinicians establish more accurate expectations regarding treatment with duloxetine.

AB - The aim of this study was to examine the longitudinal response for overall and individual symptoms during the treatment of major depressive disorder. Data were pooled from two 9-week trials, which compared duloxetine 60-mg QD (n = 251) with placebo (n = 261) in the treatment of MDD. Changes from baseline in the 17-item Hamilton Depression Rating Scale (HAMD17) and in the Visual Analog Scales for pain were analyzed. Compared to placebo-treated patients, duloxetine-treated patients experienced greater improvement (P < .05) in the HAMD17 total score at Week 2. The individual symptoms showing the most rapid improvements (Week 1) were depressed mood, guilt, suicidal ideation, work/activities, and psychic anxiety as well as VAS back pain and shoulder pain. At subsequent visits, significant improvements were observed in retardation (Week 2); hypochondriasis (Week 3); general somatic symptoms (Week 5); middle and late insomnia (Week 7); and gastrointestinal (GI) symptoms, genital symptoms (level of sexual interest or ease of sexual arousal), insight, and early insomnia (Week 9). Significant advantages for duloxetine were not achieved at any visit for agitation, somatic anxiety, or weight loss. At Weeks 1 and 2, placebo-treated patients had significantly lower GI symptoms and reported less weight loss compared with duloxetine-treated patients; however, differences were not significant at subsequent visits. Furthermore, duloxetine was superior to placebo on GI symptoms at endpoint compared to placebo-treated patients; duloxetine-treated patients had a significantly higher response rate at Week 2 and a higher remission rate at Week 5. These results may help clinicians establish more accurate expectations regarding treatment with duloxetine.

KW - Antidepressant

KW - Depression

KW - Duloxetine

KW - Efficacy

KW - Norepinephrine

KW - Onset

KW - Pain

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=23844557846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844557846&partnerID=8YFLogxK

U2 - 10.1002/da.20071

DO - 10.1002/da.20071

M3 - Article

VL - 21

SP - 170

EP - 177

JO - Depression and Anxiety

JF - Depression and Anxiety

SN - 1091-4269

IS - 4

ER -